Teva Pharmaceutical Industries Limited Company Profile (NYSE:TEVA)

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited logoTeva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules. Its central nervous system (CNS) portfolio includes Copaxone for the treatment of multiple sclerosis, Azilect for the treatment of the symptoms of Parkinson's disease and Nuvigil for the treatment of sleep disorders, as well as several therapies for the treatment of pain care. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo in the United States and Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio outside the United States. Its women's health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: TEVA
  • CUSIP:
Key Metrics:
  • Previous Close: $35.81
  • 50 Day Moving Average: $34.51
  • 200 Day Moving Average: $42.93
  • 52-Week Range: $1,015,000,000.00 - $31.90
  • Trailing P/E Ratio: 502.86
  • Foreward P/E Ratio: 7.35
  • P/E Growth: 2.09
  • Market Cap: $35.73B
  • Outstanding Shares: 1,015,000,000
  • Beta: 0.58
Profitability:
  • Net Margins: 1.50%
  • Return on Equity: 17.46%
  • Return on Assets: 7.32%
Debt:
  • Debt-to-Equity Ratio: 0.99%
  • Current Ratio: 0.90%
  • Quick Ratio: 0.62%
Additional Links:
Companies Related to Teva Pharmaceutical Industries Limited:

Analyst Ratings

Consensus Ratings for Teva Pharmaceutical Industries Limited (NYSE:TEVA) (?)
Ratings Breakdown: 1 Sell Rating, 11 Hold Ratings, 15 Buy Ratings
Consensus Rating:Buy (Score: 2.52)
Consensus Price Target: $49.25 (39.91% upside)

Analysts' Ratings History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Show:
DateFirmActionRatingPrice TargetDetails
2/17/2017J P Morgan Chase & CoSet Price TargetHold$37.00View Rating Details
2/16/2017BTIG ResearchReiterated RatingNeutral$34.00View Rating Details
2/14/2017Wells Fargo & CompanyReiterated RatingHoldView Rating Details
2/14/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$43.00View Rating Details
2/14/2017Jefferies Group LLCSet Price TargetHold$36.00 -> $33.00View Rating Details
2/14/2017RBC Capital MarketsReiterated RatingOutperform$42.00View Rating Details
2/13/2017Maxim GroupLower Price TargetHold$41.00 -> $40.00View Rating Details
2/10/2017MizuhoDowngradeBuy -> Underperform$40.00 -> $27.00View Rating Details
2/7/2017Sanford C. BernsteinSet Price TargetBuy$42.00View Rating Details
2/7/2017Citigroup Inc.Reiterated RatingBuy$47.00View Rating Details
1/31/2017Deutsche Bank AGReiterated RatingBuy$48.00View Rating Details
1/31/2017Barclays PLCLower Price TargetEqual Weight$46.00 -> $38.00View Rating Details
1/31/2017Bank of America CorpUpgradeNeutral -> BuyView Rating Details
1/10/2017Cowen and CompanyReiterated RatingBuy$100.00 -> $50.00View Rating Details
1/9/2017GabelliReiterated RatingBuyView Rating Details
12/28/2016Credit Suisse GroupReiterated RatingOutperform$47.00View Rating Details
12/23/2016GuggenheimReiterated RatingBuy$80.00View Rating Details
12/4/2016Morgan StanleyDowngradeOverweight -> Equal Weight$63.00 -> $42.00View Rating Details
11/14/2016Royal Bank Of CanadaLower Price TargetOutperform$71.00 -> $58.00View Rating Details
11/4/2016HSBC Holdings plcDowngradeBuy -> Hold$44.00 -> $66.00View Rating Details
10/7/2016Leerink SwannSet Price TargetBuy$57.00View Rating Details
9/29/2016OTR GlobalInitiated CoveragePositiveView Rating Details
8/8/2016Piper Jaffray CompaniesReiterated RatingNeutral$55.00 -> $57.00View Rating Details
7/17/2016Goldman Sachs Group, Inc. (The)Lower Price Target$70.00 -> $60.00View Rating Details
4/19/2016Canaccord GenuityReiterated RatingBuyView Rating Details
3/2/2016NomuraReiterated RatingNeutral$73.00View Rating Details
2/21/2016ArgusReiterated RatingBuy$82.00 -> $75.00View Rating Details
11/27/2015Berenberg BankLower Price TargetHold$72.00 -> $65.00View Rating Details
7/28/2015BMO Capital MarketsUpgradeMarket Perform -> Outperform$75.00 -> $80.00View Rating Details
7/27/2015Standpoint ResearchBoost Price TargetBuy$78.00 -> $84.00View Rating Details
6/3/2015Raymond James Financial, Inc.Initiated CoverageMarket PerformView Rating Details
3/31/2015CRT CapitalBoost Price TargetBuy$67.00 -> $70.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/13/2017Q416$1.36$1.38$6.26 billion$6.25 billionViewN/AView Earnings Details
11/15/2016Q316$1.29$1.31$5.71 billion$5.56 billionViewN/AView Earnings Details
8/4/2016Q216$1.20$1.25$4.86 billion$5.00 billionViewN/AView Earnings Details
5/9/2016Q116$1.17$1.20$4.78 billion$4.81 billionViewN/AView Earnings Details
2/11/2016Q415$1.29$1.28$4.83 billion$4.88 billionViewListenView Earnings Details
10/29/2015Q315$1.28$1.35$4.75 billion$4.80 billionViewListenView Earnings Details
7/30/2015Q215$1.31$1.43$4.90 billion$4.97 billionViewListenView Earnings Details
4/30/2015Q115$1.26$1.36$4.84 billion$5.00 billionViewN/AView Earnings Details
2/5/2015Q414$1.31$1.31$5.17 billion$5.17 billionViewN/AView Earnings Details
10/30/2014Q314$1.23$1.32$5.09 billion$5.06 billionViewN/AView Earnings Details
7/31/2014Q214$1.21$1.23$5.08 billion$5.00 billionViewN/AView Earnings Details
5/1/2014Q114$1.22$1.22$5.11 million$5.00 billionViewN/AView Earnings Details
2/6/2014Q413$1.26$1.42$5.19 billion$5.40 billionViewN/AView Earnings Details
10/31/2013Q313$1.26$1.27$5.00 billion$5.06 billionViewN/AView Earnings Details
8/1/2013Q213$1.20$1.20$4.94 billion$4.90 billionViewN/AView Earnings Details
5/2/2013Q113$1.10$1.12$4.85 billion$4.90 billionViewN/AView Earnings Details
2/7/2013Q412$1.33$1.32$5.26 billion$5.20 billionViewN/AView Earnings Details
11/1/2012Q312$1.25$1.28$5.08 billion$5.00 billionViewN/AView Earnings Details
8/2/2012$1.28$1.28ViewN/AView Earnings Details
5/9/2012$1.44$1.47ViewN/AView Earnings Details
2/15/2012$1.58$1.59ViewN/AView Earnings Details
11/2/2011$1.22$1.25ViewN/AView Earnings Details
7/27/2011$1.08$1.10ViewN/AView Earnings Details
5/11/2011$1.03$1.04ViewN/AView Earnings Details
2/8/2011$1.28$1.25ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Current Year EPS Consensus Estimate: $4.75 EPS
Next Year EPS Consensus Estimate: $4.79 EPS

Dividends

Current Dividend Information for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Annual Dividend:$1.16
Dividend Yield:3.30%
Dividend Growth:2.10% (3 Year Average)
Payout Ratio:1,657.38% (Based on Trailing 12 Months of Earnings)
24.42% (Based on Current Year Consensus EPS Estimate)
24.22% (Based on Next Year Consensus EPS Estimate)

Dividend History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/13/2017quarterly$0.343.7%2/28/20173/2/20173/20/2017
11/15/2016quarterly$0.3412/1/201612/5/201612/20/2016
8/4/2016quarterly$0.348/18/20168/22/20169/8/2016
5/9/2016quarterly$0.345/20/20165/24/20166/7/2016
2/16/2016Quarterly$0.292/25/20162/29/20163/14/2016
10/29/2015quarterly$0.3411/13/201511/17/201512/3/2015
7/30/2015quarterly$0.348/18/20158/20/20159/3/2015
5/5/2015special$0.342.25%5/15/20155/19/20156/4/2015
2/5/2015quarterly$0.342.36%2/17/20152/19/20153/3/2015
10/31/2014special$0.322.43%11/13/201411/17/201412/2/2014
8/1/2014quarterly$0.352.61%8/19/20148/21/20149/4/2014
5/2/2014quarterly$0.352.77%5/16/20145/20/20146/2/2014
2/4/2014$0.342/20/20142/24/20143/10/2014
11/1/2013quarterly$0.333.51%11/18/201311/20/201312/2/2013
8/5/2013quarterly$0.323.34%8/16/20138/20/20139/3/2013
8/1/2013quarterly$0.328/20/20139/2/2013
5/6/2013special$0.323.28%5/16/20135/20/20136/3/2013
2/8/2013quarterly$0.313.21%2/19/20132/21/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
DateHeadline
News IconEarnings Analysis of: Teva Pharmaceutical Industries Limited (NYSE:TEVA) (NYSE:TEVA)
oakridgeobserver.com - February 18 at 7:10 PM
News IconABR Of Teva Pharmaceutical Industries Limited (NYSE:TEVA) At 2.31 - Stock Observer (NYSE:TEVA)
www.thestockobserver.com - February 18 at 9:08 AM
nasdaq.com logoBoston Common Asset Management, LLC Buys Southwest Airlines Co, Teva Pharmaceutical Industries, ... - Nasdaq (NYSE:TEVA)
www.nasdaq.com - February 17 at 7:05 PM
nasdaq.com logoHuff WR Asset Management Co Llc Buys AT&T, Teva Pharmaceutical Industries, Arch Coal, ... - Nasdaq (NYSE:TEVA)
www.nasdaq.com - February 17 at 7:05 PM
seekingalpha.com logoTeva Pharmaceuticals Has Bottomed This Time - Seeking Alpha - Seeking Alpha (NYSE:TEVA)
seekingalpha.com - February 17 at 7:05 PM
investorplace.com logoTeva Pharmaceutical Industries Ltd (ADR) (TEVA) Is Turning Around - Investorplace.com (NYSE:TEVA)
investorplace.com - February 17 at 7:05 PM
investorplace.com logoTeva Pharmaceutical Industries Ltd (ADR) (TEVA) Is Turning Around (NYSE:TEVA)
investorplace.com - February 17 at 11:24 AM
4-traders.com logoTeva Pharmaceutical Industries : outgoing CEO earned NIS 20m in 2016 (NYSE:TEVA)
www.4-traders.com - February 16 at 8:02 PM
4-traders.com logoTeva Pharmaceutical Industries : outgoing CEO earned NIS 20m in 2016 (NYSE:TEVA)
www.4-traders.com - February 16 at 8:02 PM
News IconImpact of Brokerage Rating on Teva Pharmaceutical Industries Limited(TEVA) (NYSE:TEVA)
xboxonezone.com - February 16 at 8:02 PM
News IconImpact of Brokerage Rating on Teva Pharmaceutical Industries Limited(TEVA) (NYSE:TEVA)
xboxonezone.com - February 16 at 8:02 PM
News IconTeva Pharmaceutical Industries Limited (NYSE:TEVA)
hoyentv.com - February 16 at 8:02 PM
News IconTeva Pharmaceutical Industries Limited (NYSE:TEVA)
hoyentv.com - February 16 at 8:02 PM
capitalcube.com logoTeva Pharmaceutical Industries Ltd. :TEVA-US: Earnings Analysis: 2016 By the Numbers : February 15, 2017 (NYSE:TEVA)
us.rd.yahoo.com - February 16 at 8:02 PM
us.rd.yahoo.com logoTeva Files 2016 Annual Report on Form 20-F (NYSE:TEVA)
us.rd.yahoo.com - February 16 at 8:02 PM
marketwatch.com logoMultinationals learn the limits of being big (NYSE:TEVA)
us.rd.yahoo.com - February 16 at 8:02 PM
benzinga.com logoTeva Surrenders Some Early Gains After Q4 Beat - Benzinga (NYSE:TEVA)
www.benzinga.com - February 15 at 6:27 AM
seekingalpha.com logoTeva Management's Brilliant Hidden Message - Seeking Alpha (NYSE:TEVA)
seekingalpha.com - February 15 at 6:27 AM
capitalcube.com logoTeva Pharmaceutical Industries Ltd. :TEVA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 14, 2017 (NYSE:TEVA)
www.capitalcube.com - February 15 at 6:27 AM
finance.yahoo.com logoCompany News for February 14, 2017 (NYSE:TEVA)
finance.yahoo.com - February 15 at 6:27 AM
News IconTeva Pharmaceutical Industries Ltd. Reports Q4 Improvement Thanks to Actavis Deal - Fox Business (NYSE:TEVA)
www.foxbusiness.com - February 14 at 1:43 AM
wsj.com logo[$$] Teva Swings to Loss on Write-Down But Beats Expectations (NYSE:TEVA)
www.wsj.com - February 14 at 1:43 AM
fool.com logoTeva Pharmaceutical Industries Ltd. Reports Q4 Improvement Thanks to Actavis Deal (NYSE:TEVA)
www.fool.com - February 13 at 10:25 PM
News IconEPS Of Teva Pharmaceutical Industries Limited (NYSE:TEVA) At ... - Stock Observer (NYSE:TEVA)
www.thestockobserver.com - February 13 at 8:41 PM
investors.com logoTeva Maintains 2017 Guidance Despite Copaxone Patent Losses; Q4 Tops (NYSE:TEVA)
www.investors.com - February 13 at 8:41 PM
seekingalpha.com logoTeva Will Report Higher-Than-Expected Income - Seeking Alpha (NYSE:TEVA)
seekingalpha.com - February 13 at 3:41 PM
bloomberg.com logoTeva Said to Consider Options for Branded Generics (NYSE:TEVA)
www.bloomberg.com - February 13 at 3:41 PM
finance.yahoo.com logoTeva Said to Weigh Options for Branded Generics to Reduce Debt (NYSE:TEVA)
finance.yahoo.com - February 13 at 3:41 PM
bloomberg.com logoTeva Tries Out 'Alternative Guidance' (NYSE:TEVA)
www.bloomberg.com - February 13 at 3:41 PM
fool.com logo3 Bargain-Bin High-Yield Dividend Stocks You've Overlooked This Winter (NYSE:TEVA)
www.fool.com - February 13 at 3:41 PM
thestreet.com logoHow to Trade Monday's Most Active Stocks: BofA, Vale, Zeltiq, Teva and More (NYSE:TEVA)
www.thestreet.com - February 13 at 3:41 PM
investopedia.com logoTroubling Trends Seen in Teva's FY16 Results (NYSE:TEVA)
www.investopedia.com - February 13 at 3:41 PM
News IconABR Of Teva Pharmaceutical Industries Limited (NYSE:TEVA) At 2.19 - Stock Observer (NYSE:TEVA)
www.thestockobserver.com - February 11 at 8:44 PM
seekingalpha.com logoTeva: Get Out While You Can - Seeking Alpha (NYSE:TEVA)
seekingalpha.com - February 11 at 8:44 PM
investorplace.com logoTeva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock: Will the Slump End? - Investorplace.com (NYSE:TEVA)
investorplace.com - February 11 at 8:44 PM
forbes.com logoEarnings Preview: What To Expect From Teva Pharmaceutical On Monday (NYSE:TEVA)
www.forbes.com - February 11 at 8:44 PM
schaeffersresearch.com logoTeva Pharmaceutical Options Traders Target Puts Ahead of Earnings (NYSE:TEVA)
www.schaeffersresearch.com - February 11 at 5:11 AM
smarteranalyst.com logoTop Analyst Gets Bearish on Teva Pharmaceutical Industries Ltd (ADR) (TEVA); Here’s Why (NYSE:TEVA)
www.smarteranalyst.com - February 11 at 5:11 AM
News IconLeading stocks in today’s market: Teva Pharmaceutical Industries Limited (NYSE:TEVA) (NYSE:TEVA)
twincountynews.com - February 11 at 5:11 AM
investorplace.com logoTeva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock: Will the Slump End? (NYSE:TEVA)
investorplace.com - February 10 at 3:27 PM
News IconWhy Teva Pharmaceutical Industries Ltd (ADR) Might Be a Tasty Turnaround Stock (NYSE:TEVA)
stateofglobe.com - February 10 at 6:02 AM
prnewswire.com logoBernstein Liebhard LLP Investigates Claims On Behalf Of Shareholders Of Teva Pharmaceuticals Industries, Ltd. (NYSE:TEVA)
www.prnewswire.com - February 9 at 6:05 AM
uk.finance.yahoo.com logoDrugmaker Teva says Israel probing kickback allegations (NYSE:TEVA)
us.rd.yahoo.com - February 9 at 6:05 AM
fool.com logoAfter Copaxone, Is Teva's Future Bleak? (NYSE:TEVA)
us.rd.yahoo.com - February 9 at 6:05 AM
us.rd.yahoo.com logoTeva (TEVA) Q4 Earnings: What's in Store for the Stock? (NYSE:TEVA)
us.rd.yahoo.com - February 9 at 6:05 AM
us.rd.yahoo.com logo[$$] Teva under police investigation in home market of Israel (NYSE:TEVA)
us.rd.yahoo.com - February 9 at 6:05 AM
247wallst.com logoTeva, Kors Stagger into Tuesday's 52-Week Low Club - 24/7 Wall St. (NYSE:TEVA)
247wallst.com - February 9 at 6:05 AM
seekingalpha.com logoTeva Q4 Earnings: Brace For Impact - Seeking Alpha (NYSE:TEVA)
seekingalpha.com - February 9 at 6:05 AM
investorplace.com logoTeva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Falls on CEO Departure - Investorplace.com (NYSE:TEVA)
investorplace.com - February 9 at 6:05 AM
finance.yahoo.com logoBartosiak: Trading Teva Pharmaceutical's (TEVA) Earnings with Options (NYSE:TEVA)
finance.yahoo.com - February 9 at 6:05 AM

Social

What is Teva Pharmaceutical Industries Limited's stock symbol?

Teva Pharmaceutical Industries Limited trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How often does Teva Pharmaceutical Industries Limited pay dividends? What is the dividend yield for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited declared a quarterly dividend on Monday, February 13th. Shareholders of record on Thursday, March 2nd will be given a dividend of $0.34 per share on Monday, March 20th. This represents a $1.36 dividend on an annualized basis and a yield of 3.86%. The ex-dividend date is Tuesday, February 28th.

Where is Teva Pharmaceutical Industries Limited's stock going? Where will Teva Pharmaceutical Industries Limited's stock price be in 2017?

27 brokers have issued 1-year price targets for Teva Pharmaceutical Industries Limited's stock. Their predictions range from $27.00 to $80.00. On average, they expect Teva Pharmaceutical Industries Limited's stock price to reach $49.25 in the next year.

What are analysts saying about Teva Pharmaceutical Industries Limited stock?

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries Limited stock:

  • RBC Capital Markets analysts commented, "TEVA reported 4Q above Street expectations and reaffirmed 2017 guidance with some further color around the year. The bull case in TEVA lacks conviction and change is needed. We look to CEO search/ strategic review, potential for break-up, and potential upside from generic Copaxone surprise as opportunity but near-term confidence remains low. No change to PT but EPS moves lower to reflect greater competitive pressures." (2/14/2017)
  • Maxim Group analysts commented, "This morning, Teva reported 4Q16 and full year results; total quarterly revenues were $6.5B, up 16.7% sequentially. Revenues breakdown: $3.7B from the generic business (now includes the OTC revenues), representing a 28% increase from $2.9B in 3Q16, mainly due to the accretion of Actavis business. Specialty medicine revenues were $2.2B, including $1B in total Copaxone sales, which was down 4% from 3Q16 Copaxone revenues. The quarterly numbers translated into a net loss of $937M in 4Q16, as a result of acquisition related write-downs, goodwill impairment and financial expenses. Non-GAAP net income for 4Q16 and the full year were $1.4B or $1.38 per diluted share, and $5B or $5.14 per diluted share, respectively. Teva ended the period with $1B in cash and closed to $36B in debt. We continue to watch Copaxone market share which today we estimate accounts for 28%-29% of new and total Rx's in the U.S. We model additional share loss not yet factored into Teva's guidance; however our numbers are in-line with guidance as we assume more robust performance in generics performance." (2/13/2017)
  • According to Zacks Investment Research, "For Teva, 2016 was a transition year as it worked on the integration of Actavis Generics. Teva continues to progress with its branded and generics drugs pipeline and is looking to strengthen its biosimilar pipeline. However, in the transition period, headwinds exist in the form of fewer large generic opportunities, generic competition for Copaxone, new competition for branded products and a higher cost base. Meanwhile, the generics segment could remain under pressure due to pricing erosion as well as the absence of important new product launches. Also, Teva’s shares underperformed the generic industry this year." (12/22/2016)

Who owns Teva Pharmaceutical Industries Limited stock?

Teva Pharmaceutical Industries Limited's stock is owned by many different of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (5.58%), Barrow Hanley Mewhinney & Strauss LLC (3.20%), Highfields Capital Management LP (1.66%), Paulson & CO. Inc. (1.57%), Janus Capital Management LLC (0.42%) and Thompson Siegel & Walmsley LLC (0.42%).

Who sold Teva Pharmaceutical Industries Limited stock? Who is selling Teva Pharmaceutical Industries Limited stock?

Teva Pharmaceutical Industries Limited's stock was sold by a variety of institutional investors in the last quarter, including Investec Asset Management LTD, Orbimed Advisors LLC, Federated Investors Inc. PA, Janus Capital Management LLC, Brown Advisory Inc., Institutional Capital LLC, Investec Asset Management North America Inc. and Employees Retirement System of Texas.

Who bought Teva Pharmaceutical Industries Limited stock? Who is buying Teva Pharmaceutical Industries Limited stock?

Teva Pharmaceutical Industries Limited's stock was bought by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., Franklin Resources Inc., Highfields Capital Management LP, Barrow Hanley Mewhinney & Strauss LLC, State Street Corp, NN Investment Partners Holdings N.V., Asset Management One Co. Ltd. and Menora Mivtachim Holdings LTD..

How do I buy Teva Pharmaceutical Industries Limited stock?

Shares of Teva Pharmaceutical Industries Limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Teva Pharmaceutical Industries Limited stock cost?

One share of Teva Pharmaceutical Industries Limited stock can currently be purchased for approximately $35.20.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Earnings History Chart

Earnings by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Dividend History Chart

Dividend Payments by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Last Updated on 2/19/2017 by MarketBeat.com Staff